Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer

Troels Korshøj Bergmann, Henrik Gréen, Charlotte Brasch-Andersen, Mansoor R Mirza, Jørn Herrstedt, Berit Hølund, Andreas du Bois, Per Damkier, Werner Vach, Kim Brosen, Curt Peterson

    72 Citationer (Scopus)

    Abstract

    Paclitaxel has a broad spectrum of anti-tumor activity and is useful in the treatment of ovarian, breast, and lung cancer. Paclitaxel is metabolized in the liver by CYP2C8 and CYP3A4 and transported by P-glycoprotein. The dose-limiting toxicities are neuropathy and neutropenia, but the interindividual variability in toxicity and also survival is large. The main purpose of this study was to investigate the impact of genetic variants in CYP2C8 and ABCB1 on toxicity and survival.
    OriginalsprogEngelsk
    TidsskriftEuropean Journal of Clinical Pharmacology
    Vol/bind67
    Udgave nummer7
    Sider (fra-til)693-700
    Antal sider8
    ISSN0031-6970
    DOI
    StatusUdgivet - jul. 2011

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer'. Sammen danner de et unikt fingeraftryk.

    Citationsformater